Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis

Patent metadata

Field	Value
Publication number	US-2021186972-A1
Application number	US-201917055256-A
Country	US
Kind code	A1
Filing date	May 15, 2019
Priority date	May 15, 2018
Publication date	Jun 24, 2021
Grant date	—

Abstract

Disclosed are pharmaceutical formulations comprising a compound of formula (I): in which R1, R2, R3, and R4 are as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for treating pancreatic adenocarcinoma comprising administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and methods of detecting the change in expression levels of one or both of FoxA1 and FoxO6 in a pancreatic adenocarcinoma tumor sample from a mammal, wherein the mammal has been administered a compound of formula (I), or a pharmaceutically acceptable salt thereof.

First claim

1 . A pharmaceutical formulation comprising
(a) a compound of formula (I):

wherein R 1 is selected from the group consisting of alkyl, hydroxyalkyl, thioalkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, hydroxycycloalkyl, hydroxycycloalkylalkyl, thiocycloalkyl, alkoxycycloalkyl, alkylthiocycloalkyl, dialkylaminoalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, arylalkyl, arylalkylpiperidin-4-yl, arylpiperazinylalkyl, and heteroarylalkyl,
R 2 is phenyl, optionally substituted with one or more substituents selected from the group consisting of halo, alkyl, hydroxyalkyl, thioalkyl, alkoxy, alkylthioalkyl, alkoxycarbonyl, alkylthiocarbonyl, amino, alkylamino, dialkylamino, and alkylcarbonyl,
R 3 is phenyl, optionally substituted with one or more substituents selected from the group consisting of halo, alkyl, hydroxyalkyl, thioalkyl, alkoxy, alkylthioalkyl, alkoxy carbonyl, alkylthiocarbonyl, amino, alkylamino, dialkylamino, and alkylcarbonyl,
R 4 is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl,
or a pharmaceutically acceptable salt thereof,
wherein R 1 and R 4 are optionally substituted on the aryl and/or alkyl portion with one or more substituents selected from the group consisting of halo, alkyl, hydroxyalkyl, thioalkyl, alkoxy, alkylthioalkyl, alkoxycarbonyl, alkylthiocarbonyl, amino, alkylamino, dialkylamino, aminosulfonyl, hydroxyl, perfluoroalkoxy, alkylenedioxy, and alkylcarbonyl; and
(b) a pharmaceutically acceptable surfactant comprising one or more caprylocaproyl polyoxylglycerides and PEG-8 caprylic/capric glycerides.

2 . The formulation of claim 1 , further comprising caprylic acid.

3 . A pharmaceutical formulation comprising
(a) a compound of formula (I):

wherein R 1 is selected from the group consisting of alkyl, hydroxyalkyl, thioalkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, hydroxycycloalkyl, hydroxycycloalkylalkyl, thiocycloalkyl, alkoxycycloalkyl, alkylthiocycloalkyl, dialkylaminoalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, arylalkyl, arylalkylpiperidin-4-yl, arylpiperazinylalkyl, and heteroarylalkyl,
R 2 is phenyl, optionally substituted with one or more substituents selected from the group consisting of halo, alkyl, hydroxyalkyl, thioalkyl, alkoxy, alkylthioalkyl, alkoxycarbonyl, alkylthiocarbonyl, amino, alkylamino, dialkylamino, and alkylcarbonyl,
R 3 is phenyl, optionally substituted with one or more substituents selected from the group consisting of halo, alkyl, hydroxyalkyl, thioalkyl, alkoxy, alkylthioalkyl, alkoxy carbonyl, alkylthiocarbonyl, amino, alkylamino, dialkylamino, and alkylcarbonyl,
R 4 is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl,
or a pharmaceutically acceptable salt thereof,
wherein R 1 and R 4 are optionally substituted on the aryl and/or alkyl portion with one or more substituents selected from the group consisting of halo, alkyl, hydroxyalkyl, thioalkyl, alkoxy, alkylthioalkyl, alkoxycarbonyl, alkylthiocarbonyl, amino, alkylamino, dialkylamino, aminosulfonyl, hydroxyl, perfluoroalkoxy, alkylenedioxy, and alkylcarbonyl; and
(b) a pharmaceutically acceptable surfactant comprising one or more polyoxyethylene esters of 12-hydroxy stearic acid.

4 . The formulation of claim 1 , wherein the compound of formula (I) is metarrestin.

5 - 13 . (canceled)

14 . A method for treating pancreatic adenocarcinoma in a human, comprising administering to a human in need thereof a compound of formula (I):

wherein R 1 is selected from the group consisting of alkyl, hydroxyalkyl, thioalkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, hydroxycycloalkyl, hydroxycycloalkylalkyl, thiocycloalkyl, alkoxycycloalkyl, alkylthiocycloalkyl, dialkylaminoalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, arylalkyl, arylalkylpiperidin-4-yl, arylpiperazinylalkyl, and heteroarylalkyl,
R 2 is phenyl, optionally substituted with one or more substituents selected from the group consisting of halo, alkyl, hydroxyalkyl, thioalkyl, alkoxy, alkylthioalkyl, alkoxycarbonyl, alkylthiocarbonyl, amino, alkylamino, dialkylamino, and alkylcarbonyl,
R 3 is phenyl, optionally substituted with one or more substituents selected from the group consisting of halo, alkyl, hydroxyalkyl, thioalkyl, alkoxy, alkylthioalkyl, alkoxycarbonyl, alkylthiocarbonyl, amino, alkylamino, dialkylamino, and alkylcarbonyl,
R 4 is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl,
or a pharmaceutically acceptable salt thereof,
wherein R 1 and R 4 are optionally substituted on the aryl and/or alkyl portion with one or more substituents selected from the group consisting of halo, alkyl, hydroxyalkyl, thioalkyl, alkoxy, alkylthioalkyl, alkoxycarbonyl, alkylthiocarbonyl, amino, alkylamino, dialkylamino, aminosulfonyl, hydroxyl, perfluoroalkoxy, alkylenedioxy, and alkylcarbonyl
in an amount effective to treat pancreatic adenocarcinoma in the human.

15 . The method of claim 14 , wherein the compound of formula (I) is metarrestin.

16 . The method of claim 14 , further comprising administering to the human a chemotherapeutic agent or subjecting the human to a radiation treatment.

17 . The method of claim 14 , wherein the treating results in any one or more of (I)-(V):
(I) the disrupting of a perinucleolar compartment in a cell in the human, (II) reducing the prevalence of perinucleolar compartment in a cell in the human, (III) reducing adenosine triphosphate (ATP) levels produced by metastatic cancer cells in the human, (IV) reducing the colony formation of cancer cells in the human, and (V) reducing the migration of cancer cells in the human.

18 . The method of claim 14 , wherein the human has a stage of pancreatic adenocarcinoma selected from the group consisting of stage I pancreatic adenocarcinoma, stage II pancreatic adenocarcinoma, stage III pancreatic adenocarcinoma, and stage IV pancreatic adenocarcinoma.

19 . The method of claim 14 , wherein the human has metastatic pancreatic adenocarcinoma.

20 . The method of claim 16 , comprising administering to the human a chemotherapeutic agent.

21 . The method of claim 20 , wherein the chemotherapeutic agent is gemcitabine.

22 . The method of claim 20 , wherein the chemotherapeutic agent is administered sequentially in any order with the compound of formula (I).

23 . The method of claim 20 , wherein the chemotherapeutic agent is administered simultaneously with compound of formula (I).

24 . The method of claim 14 , wherein the compound of formula (I) reduces or delays further metastasizing of established metastases.

25 . The method of claim 14 , wherein the one or more pancreatic adenocarcinoma tumor(s) has been removed from the human by surgery.

26 . The method of claim 25 , wherein the administration of the compound of formula (I) reduces the amount or size of metastases.

27 . The method of claim 14 , wherein the administration of the compound of formula (I) re

Assignees

• The Us Secretary Department Of Health And Human Servic
• Univ Kansas
• Univ Northwestern
• Us Health

Inventors

• Rudloff Udo
• Kozlov Serguei
• Marugan Juan Jose
• Huang Sui
• Patnaik Samarjit
• Braisted John C
• Southall Noel T
• Ferrer Marc
• Dextras Christopher
• Haslam John
• Baltezor Michael

Classifications

• G01N33/57525

  of the liver or pancreas · CPC title

• A61K47/12

  Carboxylic acids; Salts or anhydrides thereof · CPC title

• A61K31/7068

  having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title

• A61K31/519 Primary

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title